The International Online Journal of Cancer & Therapeutics is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.




Jin Wang

Attending Surgeon

Graduate School : Peking Union Medical College, Tsinghua University, Beijing, China
Type of Degree : MD

2017 - China’s Most Promising Young Oncologists (2017 CSCO)
2016 - China Breast Cancer Surgery Competition, Third Prize
2013 - Nomination Award for the National Excellent Doctorial Dissertation
2012 - Outstanding Graduates Awards of Colleges and Universities in Beijing
2011-2012 - First Prize Scholarship of Peking Union Medical College
2011-2012 - Excellent Faculty of the Postgraduates in Peking Union Medical College
2009 - 11th National University Students "Challenge Cup", Third Prize

1. Wang J, Song C, Tang H, Zhang C, Tang J, Li X, Chen B, Xie X. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res. 2017;19(1):72.
2. Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):65.
3. Wang J, Zhang C, Tang H, Tang H, Tang J, Song C, Xie X. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:255-269.
4. Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, Li S, Tang H, Xie X. High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep. 2016; 6: 24502.
5. Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2016;32:1-6.
6. Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H, Xie X. Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 2014;31(9):172.
7. Wang J, Xiaoming Xie, Xi Wang, Tang J, Pan Q, Zhang Y, Di M. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer:
a meta-analysis. Surg Oncol. 2013;22:247-255.
8. Wang J, Kang WM, Yu JC, Liu YQ, Meng QB, Cao ZJ. Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NF-κB signaling pathway. Cancer Biol Ther. 2013;14:3:262-270.
9. Wang J, Yu JC, Kang WM, Liu YQ, Meng QB, Cao ZJ. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol. 2012;19(5):1529-1534.
10. Wang J, Yu JC, Kang WM, Ma ZQ. Superiority of a fish oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: a randomized clinical trial. Nutrition. 2012;28(6):623-629.
11. Wang J, Yu JC, Kang WM, Ma ZQ. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21(2):119-123.
12. Wang J, Yu JC, Kang WM, Ma ZQ. Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol. 2012;105(4):400-404.